RenalGuard Solutions offers innovative products and services aimed at preventing and reducing the incidence of kidney injury during cardiac surgery and other hospital procedures. Acute kidney injury (AKI) is a common complication of cardiac surgery, affecting up to 30% of patients and increasing morbidity and mortality rates. RenalGuard Therapy is designed to lower the risk of AKI by using a unique system that replaces urine output with a sterile replacement solution, maintaining the patient's intravascular fluid volume.

Clinical trials have shown a promising average decrease of 62% in contrast-associated AKI (CA-AKI) in over 1400 patients. RenalGuard is also under investigation in the United States. With a focus on patient safety and care, RenalGuard is CE-marked for sale in Europe and various other countries.

Discover how RenalGuard's comprehensive solution is revolutionizing kidney injury prevention in hospitals worldwide